FDA Denies MDMA Assisted Therapy for PTSD Treatment: Implications and Next Steps

FDA's Decision: A Setback for PTSD Treatment

The FDA denies MDMA assisted therapy for PTSD treatment, deeming that additional research is necessary. Advocates have rallied for the acceptance of this therapy, emphasizing its potential benefits for those struggling with post-traumatic stress disorder.

Advocacy and Reactions

• Veterans and families pushing for alternative treatments.
• Lawmakers' responses to the FDA's stance.

Implications for Future Research

The FDA's denial may hinder funding and support for trials regarding MDMA's efficacy, raising concerns about the timeline for potential approval.

Next Steps for Advocacy Groups

1. Mobilizing further research funding.
2. Advocating for continued congressional support.